[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653691":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":32,"studyPopulation":35,"armGroups":32,"interventions":32,"overallOfficials":36,"centralContacts":40,"locations":49,"responsibleParty":65,"collaborators":67,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":77,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":32,"studyType":89,"phases":32,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":95,"whyStopped":32,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":27},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with 3-Year Cumulative Incidence of Rheumatic Heart Disease","Proportion of participants who develop RHD during the 3-year follow-up period, defined according to the 2023 World Heart Federation (WHF) echocardiographic criteria. Participants will be considered to have reached the endpoint if RHD is identified on any follow-up echocardiogram at 12, 24, or 36 months, or if they are diagnosed with acute rheumatic fever (ARF) during follow-up.","3 years",[14,18,21,24],{"measure":15,"description":16,"timeFrame":17},"Rate of Newly Diagnosed Rheumatic Heart Disease","Incidence of newly diagnosed RHD at each annual assessment (12, 24, and 36 months), based on the 2023 WHF echocardiographic criteria.","12 months, 24 months, and 36 months",{"measure":19,"description":20,"timeFrame":12},"Number of Participants with RHD by Age Group","Cumulative incidence of RHD stratified by age at enrollment (5-6 years versus 7-8 years).",{"measure":22,"description":23,"timeFrame":12},"Number of Participants with RHD by Sex","Cumulative incidence of RHD stratified by participant sex.",{"measure":25,"description":26,"timeFrame":12},"Number of Participants with RHD by Geographic Location","Cumulative incidence of RHD stratified by study site (Uganda, Malawi, and The Gambia)",[28],{"measure":29,"description":30,"timeFrame":12},"Number of Participants with Acute Rheumatic Fever","Number and proportion of participants diagnosed with acute rheumatic fever during follow-up, diagnosed according to the 2015 Revised Jones Criteria. ARF events will be monitored as a safety outcome.",{"allocation":32,"interventionModel":32,"interventionModelDescription":32,"primaryPurpose":32,"observationalModel":33,"timePerspective":34,"maskingInfo":32},null,"COHORT","PROSPECTIVE","Potential participants may be identified through locally approved school-based screening programs, community-based recruitment activities, existing demographic surveillance systems, or other locally appropriate community engagement mechanisms.",[37],{"name":38,"affiliation":5,"role":39},"Andrea Beaton","PRINCIPAL_INVESTIGATOR",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":32,"email":45},"Alison Spaziani","CONTACT","703-347-3271","aspaziani@childrensnational.org",{"name":47,"role":43,"phone":48,"phoneExt":32,"email":32},"Mary Banks","513-803-3123",[50],{"facility":51,"status":32,"city":52,"state":53,"zip":32,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Uganda Heart Institute","Kampala","Uganda","UG",{"type":56,"coordinates":57},"Point",[58,59],32.58219,0.31628,{"lat":59,"lon":58},[62,63],{"name":42,"role":43,"phone":44,"phoneExt":32,"email":45},{"name":64,"role":39,"phone":32,"phoneExt":32,"email":32},"Esin Nkereuwem",{"type":66,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR",[68,69,71,73],{"name":51,"class":6},{"name":70,"class":6},"Murdoch Childrens Research Institute",{"name":72,"class":6},"Ochsner Health System",{"name":74,"class":6},"Malawi Liverpool Wellcome Programme","100653691","multi-country-evaluation-of-early-rhd-in-children-across-africa-for-vaccine-trial-readiness-100653691",false,"NCT07790302","Multi-country Evaluation of Early RHD in Children Across Africa for Vaccine Trial Readiness","A Multinational Cohort Study to Determine the Incidence of Early Rheumatic Heart Disease (MEERCATS Study 1)","MEERCATS 1","Inclusion Criteria:\n\n* Age 5-8 years at enrollment\n* Residence within participating study catchment area\n* Parent\u002Fguardian able to provide informed consent\n* Participant able to provide assent where age-appropriate (country-specific, see below)\n* Normal baseline echocardiogram according to study screening protocol\n\nExclusion Criteria:\n\n* History of past ARF or RHD with or without cardiac involvement\n* Evidence of RHD at baseline screening\n* Congenital heart disease at baseline screening (excluding small PFO\u002FASD)\n* Medical conditions that would preclude safe participation or follow-up\n* Anticipated inability to complete study follow-up","ALL","5 Years","8 Years",{"count":87,"type":88},7500,"ESTIMATED","OBSERVATIONAL","This study will look at how many children develop rheumatic heart disease (RHD) over a 3-year period. The study will include children ages 5 to 8 who do not have RHD at the start and who live in areas where the disease is common. Each child will have a heart ultrasound (echocardiogram) once a year for 3 years to check for signs of RHD. Doctors will diagnose RHD using internationally recognized guidelines from the World Heart Federation (2023). The study will also look at how often new cases occur each year, whether rates differ by age, sex, or location, and whether any children develop acute rheumatic fever during the study.",[92],"Rheumatic Heart Disease in Children",[94,92],"Rheumatic Heart Disease","NOT_YET_RECRUITING","2026-08-24",{"date":98,"type":99},"2026-08-27","ACTUAL",{"date":101,"type":88},"2027-02",{"date":103,"type":88},"2032-03-01",{"name":5,"class":6},1]